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PLASMA A T R I A L N A T R I U R E T I C F A C T O R 
I N PATIENTS W I T H CIRRHOSIS 
To the Editor: Despite intensive study, mechanisms of disturbed 
renal sodium handling in patients with cirrhosis of the liver have not 
been completely elucidated. Evidence that hyperaldosteronism can-
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not totally account for the retention of sodium and water in cirrhosis 
has prompted an increasing interest in other hormonal systems.1 
Within the past several years the existence of a circulating natriu-
retic hormone 2 , 3 and its importance in sodium retention in patients 
with cirrhosis 4" 6 have been proposed. The inability to measure and 
define this putative natriuretic hormone adequately, however, has 
impeded advances in investigating its role. 7 
Recently, the atrial natriuretic factors have emerged as novel 
regulatory peptides with natriuretic, diuretic, and smooth-muscle-
relaxant properties.8"1 1 We have demonstrated the occurrence of 
alpha-human atrial natriuretic factor — the authentic 28-amino 
acid—residue portion of the precursor hormone in human plasma 1 2 
— and have observed elevated levels of atrial natriuretic factor in 
patients with hypertension 1 3 and patients with congestive heart fail-
ure (Arendt R M , et al.: unpublished data). Here, we present data 
on plasma levels and the structure of atrial natriuretic factor in 
patients with cirrhosis. 
Nineteen patients with cirrhosis were evaluated; ascites was not 
evident in nine, was moderate in five, and was tense in five. The 
patients with ascites received spironolactone (100 to 400 mg daily 
by mouth). Twenty patients with no evidence of cardiovascular, 
renal, pulmonary, or gastrointestinal diseases served as controls. 
Measurement and molecular-weight analysis of plasma atrial natri-
uretic factor were performed as previously described. 1 2 Plasma lev-
els of atrial natriuretic factor were significantly higher in the pa-
tients with cirrhosis than in controls (5.9 to 29.1 vs. 3.5 to 18.3 
fmol per milliliter; median, 13.2 vs. 9.6 [P<0.05, two-tailed M a n n -
Whitney test]). Concentrations in the patients with tense ascites 
ranged from 7.4 to 16.5 fmol per milliliter and did not differ from 
values in the other cirrhotic patients. After spironolactone was dis-
continued in the patients with ascites, atrial natriuretic factor in-
creased by an average of 47 per cent. 
I t has been hypothesized that an inability to elaborate a natriu-
retic hormone adequately contributes to sodium retention in cirrho-
sis.1 However, plasma levels of atrial natriuretic factor in our 
cirrhotic patients were found to be even higher than normal. More-
over, the increase after discontinuation of spironolactone treatment 
does not indicate impaired release of atrial natriuretic factor in 
cirrhosis. This finding supports the opinion that the postulated na-
triuretic hormone found to be decreased in patients with cirrhosis is 
not identical with atrial natriuretic factor. 1 4 
Despite normal or elevated plasma levels of atrial natriuretic fac-
tor, structural defects of this peptide could be responsible for dimin-
ished natriuresis in cirrhotic patients. Different processing of the 
precursor hormone 1 1 might result in peptides with less diuretic 
and natriuretic effect. High-performance gel-permeation chroma-
tography, however, has not revealed the existence of precursor 
hormones. Neither gamma-human atrial natriuretic factor — the 
N-terminal-extended fragment containing alpha-human atrial na-
triuretic factor — nor other precursors could be detected. Thus, we 
have found no evidence for absolute deficiency or abnormal process-
ing of atrial natriuretic factor in cirrhosis. 
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